



## **Eurofins becomes the market leader in Environment testing services in Ireland with the acquisition of ELS and City Analysts**

**23 February 2018**

Eurofins Scientific (EUFI.PA), a global leader in environment testing, announces that it has acquired City Analysts Ltd. ("City Analysts"), a leading provider of accredited water chemistry and microbiological testing in Ireland.

City Analysts is a centre of excellence for accredited cryptosporidium analysis and toxicity testing and is unique in providing mobile laboratory services throughout Ireland. The company also has expertise in niche areas of water testing, including aquatic microbiology, toxicology and parasitology. As one of the few laboratories in Europe with accreditation for aquatic toxicity testing, City Analysts has strong links with the pharmaceutical industry in Ireland. The company, which will remain under the leadership of its management team, will add a specialist testing facility in Dublin and Clare and 37 employees to Eurofins' existing workforce in Ireland, as well as a distribution and collection network, covering all of Ireland.

The City Analysts acquisition is the second transaction completed by Eurofins Ireland in the past 12 months after the acquisition of Environmental Laboratory Services ("ELS") in the summer of 2017, and highlights Eurofins' commitment to further grow its Environment testing global footprint. Following these acquisitions, Eurofins' environment testing business has significantly expanded its service offering and its range of highly specialist laboratory services in Ireland. Moreover, Eurofins recently significantly expanded its laboratories and facilities in Dungarvan, Ireland, allowing the Group to double the volume of samples tested annually at this site. As a result of all these recent developments, Eurofins has become the number one environment testing player in Ireland, offering the most comprehensive portfolio of state-of-the-art environment testing services in the region.

Comment from **Dr. Gilles Martin**, Eurofins CEO: "We are extremely pleased to welcome City Analysts and ELS to the Eurofins Group. These acquisitions, together with the expansion of our Dungarvan facilities, are an example of our commitment to Ireland and they reinforce Eurofins' environment testing portfolio and expand the range of services offered to our clients. The City Analysts team is an excellent addition to the Eurofins family of businesses. They share our commitment to quality, customer focus, team spirit and integrity, ensuring that our customers continue to benefit from our trusted support but with even more capabilities. Bringing colleagues from City Analysts together with ELS means we can extend our range of services and maximise the benefits we can bring to our Irish clients."

**For more information, please visit [www.eurofins.com](http://www.eurofins.com) or contact:**

Investor Relations  
Eurofins Scientific  
Phone: +32 2 766 1620  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

**Notes for the editor:**

**Eurofins – a global leader in bio-analysis**

Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is the world leader

in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agrosience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

**Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.